Document is current
Any future updates will be listed below
-
Authors
Fendler, Annika https://orcid.org/0000-0002-7267-0981
Au, Lewis https://orcid.org/0000-0001-5877-8657
Shepherd, Scott T. C. https://orcid.org/0000-0001-6208-173X
Byrne, Fiona
Cerrone, Maddalena https://orcid.org/0000-0002-6900-6086
Boos, Laura Amanda
Rzeniewicz, Karolina
Gordon, William https://orcid.org/0000-0002-8166-2641
Shum, Benjamin
Gerard, Camille L.
Ward, Barry
Xie, Wenyi
Schmitt, Andreas M.
Joharatnam-Hogan, Nalinie
Cornish, Georgina H. https://orcid.org/0000-0002-1984-6677
Pule, Martin https://orcid.org/0000-0002-8347-9867
Mekkaoui, Leila https://orcid.org/0000-0001-8640-840X
Ng, Kevin W.
Carlyle, Eleanor
Edmonds, Kim
Rosario, Lyra Del
Sarker, Sarah
Lingard, Karla
Mangwende, Mary
Holt, Lucy
Ahmod, Hamid
Stone, Richard
Gomes, Camila https://orcid.org/0000-0003-2094-8141
Flynn, Helen R. https://orcid.org/0000-0001-7002-9130
Agua-Doce, Ana
Hobson, Philip
Caidan, Simon
Howell, Michael https://orcid.org/0000-0003-0912-0079
Wu, Mary https://orcid.org/0000-0002-2074-6171
Goldstone, Robert
Crawford, Margaret
Cubitt, Laura
Patel, Harshil https://orcid.org/0000-0003-2707-7940
Gavrielides, Mike
Nye, Emma
Snijders, Ambrosius P. https://orcid.org/0000-0002-5416-8592
MacRae, James I. https://orcid.org/0000-0002-1464-8583
Nicod, Jerome https://orcid.org/0000-0003-2459-3480
Gronthoud, Firza
Shea, Robyn L. https://orcid.org/0000-0002-7596-4555
Messiou, Christina
Cunningham, David https://orcid.org/0000-0001-5158-1069
Chau, Ian https://orcid.org/0000-0003-0286-8703
Starling, Naureen
Turner, Nicholas
Welsh, Liam
van As, Nicholas
Jones, Robin L.
Droney, Joanne
Banerjee, Susana
Tatham, Kate C. https://orcid.org/0000-0003-3080-8011
Jhanji, Shaman https://orcid.org/0000-0002-1116-628X
O’Brien, Mary
Curtis, Olivia https://orcid.org/0000-0002-1509-7023
Harrington, Kevin https://orcid.org/0000-0002-6014-348X
Bhide, Shreerang
Bazin, Jessica
Robinson, Anna
Stephenson, Clemency
Slattery, Tim
Khan, Yasir
Tippu, Zayd
Leslie, Isla
Gennatas, Spyridon https://orcid.org/0000-0002-5635-7696
Okines, Alicia
Reid, Alison
Young, Kate
Furness, Andrew J. S.
Pickering, Lisa https://orcid.org/0000-0002-7579-340X
Gandhi, Sonia
Gamblin, Steve https://orcid.org/0000-0001-5331-639X
Swanton, Charles https://orcid.org/0000-0002-4299-3018
,
Nicholson, Emma
Kumar, Sacheen https://orcid.org/0000-0002-4692-4554
Yousaf, Nadia https://orcid.org/0000-0003-2090-0025
Wilkinson, Katalin A. https://orcid.org/0000-0002-9796-2040
Swerdlow, Anthony
Harvey, Ruth
Kassiotis, George https://orcid.org/0000-0002-8457-2633
Larkin, James
Wilkinson, Robert J.
Turajlic, Samra https://orcid.org/0000-0001-8846-136X
,
- License Information
-
More Information
Article History
Received: 23 August 2021
Accepted: 17 September 2021
First Online: 27 October 2021
Competing interests
: S.T. has received speaking fees from Roche, AstraZeneca, Novartis and Ipsen. S.T. has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 and PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB. N.Y. has received conference support from Celegene. A.R. received speaker’s fees from Janssen and AstraZeneca; travel support from Janssen and Astellas, and consultancy fees from AstraZeneca. D.C. received funding from MedImmune, AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene and Roche, and is on the advisory board of OVIBIO. J.L. has received research funding from Bristol-Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics and Aveo, and served as a consultant to Achilles, Astra Zeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna and Vitaccess. I.C. has served as a consultant to Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck Serono, Five Prime Therapeutics, Astra Zeneca, OncXerna, Pierre Fabre, Boehringer-Ingelheim, Incyte, Astella, GSK, Sotio and, Eisai; has received research funding from Eli-Lilly & Janssen-Cilag; and has received honorarium from Eli-Lilly, Eisai, Servier. A.O. acknowledges receipt of research funding from Pfizer and Roche; speakers fees from Pfizer, Seagen, Lilly and Astra Zeneca; is an advisory board member of Roche, Seagen and Astra Zeneca; and has received conference support from Leo Pharmaceuticals, Astra Zeneca/Diachi-Sankyo and Lilly. C. Swanton acknowledges grant support from Pfizer, Astra Zeneca, Bristol-Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical; is an Astra Zeneca Advisory Board member and Chief Investigator for the MeRmaiD1 clinical trial; has consulted for Amgen, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol-Myers Squibb, Celgene, Astra Zeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Metabomed, Bicycle Therapeutics and the Sarah Cannon Research Institute; has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL and has stock options; and is co-founder of Achilles Therapeutics. C. Swanton holds European patents relating to assay technology to detect tumor recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune-checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (human leukocyte antigen loss of heterozygosity) (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumor mutations (PCT/US2017/28013) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). L.P. has received research funding from Pierre Fabre and honoraria from Pfizer, Ipsen, Bristol-Myers Squibb and EUSA Pharma. S.B. has received institutional research funding from AstraZeneca, Tesaro, GSK; speakers fees from Amgen, Pfizer, Astra Zeneca, Tesaro, GSK, Clovis, Takeda, Immunogen and Mersana; and has an advisory role for Amgen, AstraZeneca, Epsilogen, Genmab, Immunogen, Mersana, Merck Sharp & Dohme, Merck Serono, Oncxerna, Pfizer and Roche. N.T. has received advisory board honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, GlaxoSmithKline, Zentalis Pharmaceuticals, Repare Therapeutics and Arvinas; and research funding from AstraZeneca, BioRad, Pfizer, Roche/Genentech, Merck Sharpe & Dohme, Guardant Health, Invitae, Inivata, Personalis and Natera. M.O.B. is on advisory boards for Amgen, Pierre Fabre, Pharmamar, Puma, MSD and Roche. A.M.S. received and educational grant from Janssen-Cilag. N.S. received travel grants from AstraZeneca, BMS, Eli Lilly, Merck, Roche and MSD Oncology; received honoraria from Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier, GSK and Amgen; and is on the advisory board for Pfizer, AstraZeneca, Servier and MSD. N.S. received funding from AstraZeneca, BMS, Pfizer, NIHR EME, RMCC and RM/ICR BCR. R.L.J. received research support from Merck Sharp & Dohme and GSK; and received consultation fees from Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Cinigen, Eisai, Epizyme, Daichii, Deciphera, Immundesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, Pharmamar, Springworks, SynOx, Tracon, Upto Date and Merck Sharp & Dohme<i>.</i> A.F., L.A., S.T.C.S., F.B., M.C., L.A.B., K.R., W.G., B.S., C.L.G., B.W., W.X., N.J.-H., G.H.C., M.P., L.M., K.W.N., E.C., K.E., L.D.R., S.S., K.L., M.M., L.H., H.A., R.S., C.G., H.R.F., A.A.-D., P.H., S.C., M.H., M.W., R.G., M.C., L.C., H.P., M.G., E.N., A.-.S., J.I.M., J.N., F.G., R.L.S., C.M., D.C. L.W., N.v.A., J.D., K.C.T., S.J., O.C., K.H., S.B., J.B., A. Robinson, C. Stephenson, T.S., Y.K., Z.T., I.L., S.G., A.O., A. Reid, K.Y., A.J.S.F., S. Gamblin, C. Swanton, E.N., S.K., K.A.W., A.S., R.H., G.K. and R.J.W. declare no competing interests.
